DK3706796T3 - Eksosomerer som RNA terapeutikske midler - Google Patents

Eksosomerer som RNA terapeutikske midler Download PDF

Info

Publication number
DK3706796T3
DK3706796T3 DK18806990.0T DK18806990T DK3706796T3 DK 3706796 T3 DK3706796 T3 DK 3706796T3 DK 18806990 T DK18806990 T DK 18806990T DK 3706796 T3 DK3706796 T3 DK 3706796T3
Authority
DK
Denmark
Prior art keywords
exosomes
therapeutic agents
rna therapeutic
rna
agents
Prior art date
Application number
DK18806990.0T
Other languages
English (en)
Inventor
Lorenzo Errichelli
Dhanu Gupta
Justin Hean
Joel NORDIN
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664781&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3706796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Application granted granted Critical
Publication of DK3706796T3 publication Critical patent/DK3706796T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18806990.0T 2017-11-08 2018-11-08 Eksosomerer som RNA terapeutikske midler DK3706796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1718471.4A GB2568255A (en) 2017-11-08 2017-11-08 Exosomes comprising RNA therapeutics
PCT/EP2018/080681 WO2019092145A1 (en) 2017-11-08 2018-11-08 Exosomes comprising rna therapeutics

Publications (1)

Publication Number Publication Date
DK3706796T3 true DK3706796T3 (da) 2021-11-22

Family

ID=60664781

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18806990.0T DK3706796T3 (da) 2017-11-08 2018-11-08 Eksosomerer som RNA terapeutikske midler

Country Status (18)

Country Link
US (1) US20210369865A1 (da)
EP (2) EP3706796B1 (da)
JP (2) JP7077404B2 (da)
KR (1) KR102431418B1 (da)
CN (1) CN111629760B (da)
AU (1) AU2018365299B2 (da)
BR (1) BR112020006960A2 (da)
CA (1) CA3082194C (da)
DK (1) DK3706796T3 (da)
ES (1) ES2899857T3 (da)
GB (1) GB2568255A (da)
IL (1) IL274125B (da)
MX (1) MX2020004698A (da)
PT (1) PT3706796T (da)
RU (1) RU2020118554A (da)
SG (1) SG11202004199PA (da)
WO (1) WO2019092145A1 (da)
ZA (1) ZA202002537B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019122461A (ja) * 2018-01-12 2019-07-25 株式会社三洋物産 遊技機
JP2019122462A (ja) * 2018-01-12 2019-07-25 株式会社三洋物産 遊技機
JP2019136401A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136400A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136398A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
JP2019136399A (ja) * 2018-02-14 2019-08-22 株式会社三洋物産 遊技機
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
GB201810301D0 (en) * 2018-06-22 2018-08-08 Evox Therapeutics Ltd Combinatorial gene therapy
GB201906482D0 (en) * 2019-05-08 2019-06-19 Evox Therapeutics Ltd Exosome comprising stabilized RNA therapeutics
WO2021095842A1 (ja) * 2019-11-15 2021-05-20 国立大学法人 東京大学 バーコード化された細胞外小胞のライブラリー
KR20220147107A (ko) * 2020-02-28 2022-11-02 도쿠리츠다이가쿠호징 가나자와다이가쿠 면역 제어법, 면역 제어용 핵산 조성물 및 그의 용도
US20230096378A1 (en) 2020-03-12 2023-03-30 Institute For Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
CN111424017B (zh) * 2020-03-27 2022-08-09 暨南大学 一种装载shRNA的外泌体及其构建方法与应用
WO2021223659A1 (en) * 2020-05-06 2021-11-11 Nanjing Iaso Biotherapeutics Co., Ltd. Extracellular vesicles targeting cancer cells and uses thereof
CN111647045B (zh) * 2020-06-17 2022-05-27 清华大学深圳国际研究生院 一种cd133拮抗多肽及其衍生物与应用
GB202010278D0 (en) 2020-07-03 2020-08-19 Evox Therapeutics Ltd Extracellular vesicles with improved half-life
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
CN112626068B (zh) * 2020-12-21 2021-12-03 徐州医科大学 一种靶向Notch1基因的LncRNA及其应用
WO2022206781A1 (zh) * 2021-03-30 2022-10-06 南京大学 一种用于治疗结肠炎的rna递送***
GB202105925D0 (en) 2021-04-26 2021-06-09 Evox Therapeutics Ltd Modified extracellular vesicles (EVs) with improved half-life
WO2023284380A1 (zh) * 2021-07-15 2023-01-19 呈诺再生医学科技(北京)有限公司 细胞作为基因治疗的载体在临床中的应用
WO2023001894A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023033124A1 (ja) * 2021-09-01 2023-03-09 国立大学法人金沢大学 免疫制御法、免疫制御用核酸組成物およびその用途
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
CN114569721B (zh) * 2022-02-25 2023-03-24 浙江大学 载药的胞外囊泡在制备治疗肥胖或减轻肥胖相关代谢指标的药物中的应用
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
GB202210861D0 (en) * 2022-07-25 2022-09-07 Univ Oxford Innovation Ltd Loaded extracellular vesicle
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2419144T3 (da) 2009-04-17 2019-10-21 Univ Oxford Innovation Ltd Sammensætning til levering af genetisk materiale
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
KR20160089527A (ko) * 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
EP3440090B1 (en) * 2016-04-06 2022-09-28 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides

Also Published As

Publication number Publication date
GB2568255A (en) 2019-05-15
CA3082194C (en) 2022-10-04
CN111629760B (zh) 2023-09-05
US20210369865A1 (en) 2021-12-02
CA3082194A1 (en) 2019-05-16
CN111629760A (zh) 2020-09-04
ES2899857T3 (es) 2022-03-15
EP3706796A1 (en) 2020-09-16
JP2022113690A (ja) 2022-08-04
EP3973989A1 (en) 2022-03-30
SG11202004199PA (en) 2020-06-29
BR112020006960A2 (pt) 2020-10-13
GB201718471D0 (en) 2017-12-20
AU2018365299B2 (en) 2021-12-16
KR102431418B1 (ko) 2022-08-16
EP3706796B1 (en) 2021-09-29
JP2021507682A (ja) 2021-02-25
PT3706796T (pt) 2021-11-24
WO2019092145A1 (en) 2019-05-16
IL274125B (en) 2022-07-01
MX2020004698A (es) 2022-01-17
RU2020118554A (ru) 2021-12-08
JP7077404B2 (ja) 2022-05-30
AU2018365299A1 (en) 2020-05-28
RU2020118554A3 (da) 2022-04-20
KR20200086322A (ko) 2020-07-16
ZA202002537B (en) 2022-07-27
IL274125A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
DK3688162T3 (da) Formuleringer
MA47680A (fr) Arn thérapeutique
MA40764A (fr) Agent thérapeutique induisant une cytotoxicité
DK3107563T3 (da) Glycomålrettede terapeutiske midler
GB201513540D0 (en) Therapeutic agents
MA42844A (fr) Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
GB201509893D0 (en) Therapeutic agents
DK3235550T3 (da) Forlystelse
MA50541A (fr) Formulations pharmaceutiques
DK3474802T3 (da) Medicinsk forbinding
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
MA39483A (fr) Agents thérapeutiques cibles
GB201517263D0 (en) Therapeutic agents
BR112018005409A2 (pt) terapêutica de glicodirecionamento.
MA42303A (fr) Formulations pharmaceutiques
DK3393478T3 (da) Kombinationsterapi
DK3373874T4 (da) Medicinsk forbinding
DK3164117T3 (da) Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider
DK3408265T3 (da) Terapeutiske forbindelser
GB201509885D0 (en) Therapeutic agents
DK3315131T3 (da) Terapeutisk middel mod fibrose
DK3302016T3 (da) Ophængt plov
GB201509888D0 (en) Therapeutic agents
DK3280447T3 (da) Farmaceutiske formuleringer